Takeda to manufacture J&J's COVID-19 vaccine

Japanese drugmaker Takeda signed an agreement March 15 to use contract development and manufacturing company IDT Biologika's facility, which was previously reserved for Takeda’s dengue vaccine candidate, to manufacture Johnson & Johnson's COVID-19 vaccine.

The facility, located in Dessau, Germany, will go back to producing Takeda's dengue vaccine candidate after a three-month period. 

Takeda has agreed to help manufacture three different COVID-19 vaccines. The drugmaker has already begun manufacturing Moderna and Novavax vaccines to provide rapid and sustained COVID-19 vaccine access in Japan.

More articles on pharmacy:
No link between AstraZeneca vaccine, blood clots, WHO says, despite countries halting use
HHS allows retired pharmacists, pharmacy interns to give COVID-19 vaccinations
Gilead, Merck co-developing long-acting HIV treatment

 
 

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars